{"component": "definition", "props": {"groups": [{"size": 9, "snippet": "means the pharmaceutical product in solid, oral tablet form containing 10mg of the Compound as its sole active pharmaceutical agent as described in the Initial Product NDA as of the Effective Date.", "samples": [{"hash": "6E1O6QTFSzG", "uri": "/contracts/6E1O6QTFSzG#initial-formulation", "label": "Transaction Agreement", "score": 31.340862423, "published": true}, {"hash": "eOX2fafHhW5", "uri": "/contracts/eOX2fafHhW5#initial-formulation", "label": "Supply Agreement (Arena Pharmaceuticals Inc)", "score": 28.3401779603, "published": true}, {"hash": "eyNjNvvhHOf", "uri": "/contracts/eyNjNvvhHOf#initial-formulation", "label": "Transaction Agreement (Arena Pharmaceuticals Inc)", "score": 28.2005475702, "published": true}], "snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [10, 32]}, {"key": "pharmaceutical-agent", "type": "clause", "offset": [111, 131]}, {"key": "initial-product-nda", "type": "definition", "offset": [152, 171]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [172, 196]}], "hash": "2083018de7601c2dbeba3ac17b7a3163", "id": 1}, {"size": 4, "snippet": "means the pharmaceutical product in solid, oral tablet form containing the Compound as its sole active pharmaceutical agent as described in the Initial Product NDA as of the Effective Date.", "samples": [{"hash": "fprzFGrOWX3", "uri": "/contracts/fprzFGrOWX3#initial-formulation", "label": "Marketing and Supply Agreement (Arena Pharmaceuticals Inc)", "score": 21.8542094456, "published": true}, {"hash": "74EGzfdU1JI", "uri": "https://invest.arenapharm.com/static-files/a9cbc3ab-cf6c-4f18-aec4-a7deac605b66", "label": "invest.arenapharm.com", "score": 9.9637234771, "published": false}, {"hash": "2XXZJsDQxXb", "uri": "https://invest.arenapharm.com/static-files/35704a35-5e53-4f1a-b42b-1aabceeb23f9", "label": "invest.arenapharm.com", "score": 9.0533880903, "published": false}], "snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [10, 32]}, {"key": "pharmaceutical-agent", "type": "clause", "offset": [103, 123]}, {"key": "initial-product-nda", "type": "definition", "offset": [144, 163]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [164, 188]}], "hash": "2179af36c594611c287d9bc28e7fe6d6", "id": 2}, {"size": 3, "snippet": "means the formulation of the Licensed Product for the Initial Indication (a) intended to be used for the first Phase 3 Clinical Trial immediately following Acucela\u2019s exercise of its Opt-In Right, if Acucela exercises the * Opt-In Right, or (b) intended to be used for purposes of filing the first NDA, if Acucela exercises the P3 Opt-In Right.", "samples": [{"hash": "4WUkhsiRqeu", "uri": "/contracts/4WUkhsiRqeu#initial-formulation", "label": "Development and Collaboration Agreement", "score": 31.340862423, "published": true}, {"hash": "4b0lEmIkjdr", "uri": "/contracts/4b0lEmIkjdr#initial-formulation", "label": "Development and Collaboration Agreement (Acucela Inc)", "score": 24.9589322382, "published": true}, {"hash": "bVleYhRTXlg", "uri": "/contracts/bVleYhRTXlg#initial-formulation", "label": "Development and Collaboration Agreement (Acucela Inc)", "score": 24.5071868583, "published": true}], "snippet_links": [{"key": "licensed-product", "type": "clause", "offset": [29, 45]}, {"key": "initial-indication", "type": "definition", "offset": [54, 72]}, {"key": "phase-3-clinical-trial", "type": "definition", "offset": [111, 133]}, {"key": "exercise-of", "type": "clause", "offset": [166, 177]}, {"key": "for-purposes-of", "type": "clause", "offset": [264, 279]}], "hash": "1cf008b320f70ce91c3da09de1b96a03", "id": 3}, {"size": 3, "snippet": "means the formulation of the Lead Compound set forth on Exhibit C.", "samples": [{"hash": "5qsmrYlyOQm", "uri": "/contracts/5qsmrYlyOQm#initial-formulation", "label": "Co Development and Commercialization Agreement", "score": 31.340862423, "published": true}, {"hash": "ddB9yMGR4ZV", "uri": "/contracts/ddB9yMGR4ZV#initial-formulation", "label": "Co Development and Commercialization Agreement (Acucela Inc.)", "score": 25.0711841205, "published": true}, {"hash": "hjeQEdlRlxR", "uri": "/contracts/hjeQEdlRlxR#initial-formulation", "label": "Co Development and Commercialization Agreement (Acucela Inc)", "score": 24.5071868583, "published": true}], "snippet_links": [{"key": "lead-compound", "type": "definition", "offset": [29, 42]}], "hash": "aa303bf5b3d072c0543c6360f8d5f6a5", "id": 4}, {"size": 2, "snippet": "shall have the meaning as such term is defined in Clause 2.3 of the JDOA.", "samples": [{"hash": "5j4fnEYqDlD", "uri": "/contracts/5j4fnEYqDlD#initial-formulation", "label": "License Agreement (Safescience Inc)", "score": 18.0, "published": true}, {"hash": "1OnckQFVgDd", "uri": "/contracts/1OnckQFVgDd#initial-formulation", "label": "License Agreement (Safescience Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "in-clause", "type": "clause", "offset": [47, 56]}], "hash": "7063b31266c8149b4822b56f0de0c281", "id": 5}, {"size": 2, "snippet": "means the oral formulation of a Product in non-enteric coated soft gel capsules which is specified in each NDA application for the Product for Constipation and C-IBS indications in the Initial Territory.", "samples": [{"hash": "fy1KL448wUe", "uri": "/contracts/fy1KL448wUe#initial-formulation", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}, {"hash": "fbffL2QHwh5", "uri": "/contracts/fbffL2QHwh5#initial-formulation", "label": "Collaboration and License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "oral-formulation", "type": "definition", "offset": [10, 26]}, {"key": "the-product", "type": "clause", "offset": [127, 138]}, {"key": "initial-territory", "type": "definition", "offset": [185, 202]}], "hash": "312c898b58229411925c063d1b90877f", "id": 6}, {"size": 1, "snippet": "shall have the meaning as such term is defined in Clause 2.3.", "samples": [{"hash": "19aHL3ZaXnJ", "uri": "/contracts/19aHL3ZaXnJ#initial-formulation", "label": "Subscription, Joint Development and Operating Agreement (Safescience Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "in-clause", "type": "clause", "offset": [47, 56]}], "hash": "2dbd4edf8ef3e8cc182a64072f277639", "id": 7}, {"size": 1, "snippet": "means the subcutaneous formulation of the Compound.", "samples": [{"hash": "f22uAL0NIUv", "uri": "/contracts/f22uAL0NIUv#initial-formulation", "label": "License Agreement (Progenics Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [], "hash": "aa5f4421ab8c31b7f24bac09fe56c85a", "id": 8}, {"size": 1, "snippet": "means the oral formulation of a Product in non-enteric coated soft gel capsules which is specified in each NDA application for the Product for Constipation and C-IBS indications in the Initial Territory. \u201cInitial Indications\u201d shall mean all gastroenterology indications, including but not limited to, Constipation and C-IBS for the Product. \u201cInitial Territory\u201d shall mean the United States and Canada. \u201cJCC\u201d shall have the meaning set forth in Section 5.1(a). \u201cJDC\u201d shall have the meaning set forth in Section 4.1(a). \u201cJMC\u201d shall have the meaning set forth in Section 6.1(a). \u201cJSC\u201d shall have the meaning set forth in Section 3.1(a). \u201cLabeling Changes\u201d shall have the meaning set forth in Section 4.2 (b)(iii). \u201cLiability\u201d shall have the meaning set forth in Section 10.1. \u201cLicensed Know-How\u201d shall mean all information and data, regardless of form, which is owned by or licensed (with right of sublicense) to SPI as of the Effective Date or at anytime during the", "samples": [{"hash": "a9lub0q6F8l", "uri": "/contracts/a9lub0q6F8l#initial-formulation", "label": "Collaboration and License Agreement", "score": 31.340862423, "published": true}], "snippet_links": [{"key": "oral-formulation", "type": "definition", "offset": [10, 26]}, {"key": "the-product", "type": "clause", "offset": [127, 138]}, {"key": "initial-territory", "type": "definition", "offset": [185, 202]}, {"key": "initial-indications", "type": "definition", "offset": [205, 224]}, {"key": "not-limited", "type": "clause", "offset": [285, 296]}, {"key": "united-states-and-canada", "type": "clause", "offset": [376, 400]}, {"key": "labeling-changes", "type": "clause", "offset": [635, 651]}, {"key": "section-42", "type": "clause", "offset": [689, 700]}, {"key": "licensed-know", "type": "definition", "offset": [774, 787]}, {"key": "information-and-data", "type": "clause", "offset": [808, 828]}, {"key": "owned-by", "type": "definition", "offset": [859, 867]}, {"key": "right-of-sublicense", "type": "clause", "offset": [886, 905]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [914, 938]}], "hash": "4dd53f6d7a6fd90b77325ee6983a58bd", "id": 9}, {"size": 1, "snippet": "means the oral formulation of Drug Product in soft gelatin capsules as of the Effective Date.", "samples": [{"hash": "kTcGP1Ikon1", "uri": "/contracts/kTcGP1Ikon1#initial-formulation", "label": "Exclusive Manufacturing and Supply Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 25.848733744, "published": true}], "snippet_links": [{"key": "oral-formulation", "type": "definition", "offset": [10, 26]}, {"key": "drug-product", "type": "definition", "offset": [30, 42]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [68, 92]}], "hash": "97fc06a268d244b98349083207cb4565", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIcaW5pdGlhbC1mb3JtdWxhdGlvbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 28, "snippet": "means the pharmaceutical product in solid, oral tablet form containing 10mg of the Compound as its sole active pharmaceutical agent as described in the Initial Product NDA as of the Effective Date.", "title": "Initial Formulation", "id": "initial-formulation", "examples": ["As soon as practicable after formation of the JCC (following Acucela\u2019s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the <strong>Initial Formulation</strong> (and, if applicable, any New Formulation or Other Indication Product) in the Territory.", "The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the <strong>Initial Formulation</strong> is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the \u201cGeneral Commercialization Plan Outline\u201d).", "For clarity, Acucela shall have no opt-in right under this Section 3.2(b), and shall have no right to co-Develop or Co-Promote an Other Indication Product, if Acucela does not exercise its Opt-In Right with respect to the Initial Indication in the <strong>Initial Formulation</strong> under Section 3.1.", "In accordance with this Section 3.1, Acucela shall have an opt-in right to co-Develop and Co-Promote with Otsuka (and its Affiliates) the Licensed Compound and Licensed Products for the Initial Indication in the <strong>Initial Formulation</strong> in the Territory pursuant to Development Plans, Commercialization Plans and the terms of this Agreement.", "If Acucela exercises an Opt-In Right under Section 3.1, the Parties shall Co-Promote the Licensed Product for the Initial Indication in the <strong>Initial Formulation</strong> in the Territory in accordance with the Commercialization Plan and the Co-Promotion Agreement.", "For clarity, Acucela shall have no opt-in right under this Section 3.3(b), and shall have no right to co-Develop or Co-Promote a New Formulation, if Acucela does not exercise its Opt-In Right with respect to the Initial Indication in the <strong>Initial Formulation</strong> under Section 3.1.", "If Acucela exercises an Opt-In Right under Section 3.1, the Parties shall jointly Develop the Licensed Compound and Licensed Products for the Initial Indication in the <strong>Initial Formulation</strong> in the Territory in accordance with the Development Plan.", "Notwithstanding anything to the contrary contained in this Article 4, the Parties shall meet and discuss in good faith the Clinical Supply Price and the Commercial Supply Price for any and all formulations other than the <strong>Initial Formulation</strong> and matching placebo in accordance with Article 13.1 below.", "SPI shall conduct all Development work necessary for an NDA submission in the Initial Territory for Constipation and C-IBS in the <strong>Initial Formulation</strong>.", "Article 1.1. &quot;Additional Formulation&quot; means any and all formulations other than the <strong>Initial Formulation</strong>."], "related": [["formulation", "Formulation", "Formulation"], ["biological-samples", "Biological Samples", "Biological Samples"], ["biological-product", "Biological product", "Biological product"], ["replacement-product", "Replacement Product", "Replacement Product"], ["special-food-product", "Special food product", "Special food product"]], "related_snippets": [], "updated": "2025-07-06T21:55:40+00:00"}, "json": true, "cursor": ""}}